Log In
Friday 28th October 2016

Alzheimer drug decision challenged

16th January 2007

NICE looks set to go to court to defend its decision to limit the use of treatment for Alzheimer's disease.

The National Institute for Health and Clinical Excellence ruled in November that three Alzheimer's drugs - donepezil (Aricept), galantamine (Reminyl) and rivastigimine (Exelon) - should only be used for patients with moderate levels of the disease and not used for new patients.

Now a drug firm has confirmed its plan to challenge this decision in the High Court after NICE refused to reveal details of its decision-making process on cost effectiveness.

Eisai which holds the licence for Aricept, supported by Pfizer, which markets it, have formally applied for a judicial review. The move is being supported by the Alzheimer’s Society.

NICE has stood by its decision, and claims there is no foundation for a review.

Share this page


There are no comments for this article, be the first to comment!

Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

M3 - For secure managed hosting over N3 or internet
© Mayden Foundation 2016